Article Text

Download PDFPDF
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
  1. Michael Bonelli,
  2. Daniel Aletaha
  1. Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Professor Daniel Aletaha, Department of Rheumatology, Medical University of Vienna, 1090 Wien, Austria; daniel.aletaha{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read the correspondence of Westhoff et al to our article1 with great interest. The authors confirm our finding of an impaired humoral immune response in rituximab-treated patients by showing that also their rituximab treated patients did not develop antibodies to the SARS-CoV-2 spike protein after two doses of SARS-CoV-2 vaccinations with BNT162b2.2 In line with our data, the authors provide evidence for a maintained cellular immune response in rituximab-treated patients. In addition, Westhoff et al could …

View Full Text


  • Handling editor Gerd-Rüdiger R Burmester

  • Contributors MB and DA drafted this response.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles